Urinary Bladder Neoplasm Clinical Trial
Official title:
Holmium Versus Bipolar en Bloc Transurethral Resection of Urothelium Tumor of the Urinary Bladder: A Randomized Controlled Trial
Verified date | October 2020 |
Source | Ain Shams University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
En bloc resection of bladder tumors (ERBT) may improve staging quality and perioperative morbidity and influence tumour recurrence
Status | Recruiting |
Enrollment | 70 |
Est. completion date | August 1, 2021 |
Est. primary completion date | August 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Adult patients of both sexes presented with urinary bladder tumor aiming for complete resection as diagnosed by Ultrasound with or without CT prior histopathological assessment. Exclusion Criteria: - Patients with signs of extravesical tumor extension where complete resection will not beneficial or unable to proceed to complete resection due to huge tumor burden either huge single tumor more than 5 cm or multiple tumors that are not candidate for complete resection. |
Country | Name | City | State |
---|---|---|---|
Egypt | Ain Shams University Hospitals | Cairo |
Lead Sponsor | Collaborator |
---|---|
Ain Shams University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | number of participant with Conversion to the TURBT | conversion from the enbloc way of resection to the standard trans-urethral resection of bladder tumors | intraoperative finding | |
Secondary | Operative time | calculation of operative time in minutes | intraoperative finding | |
Secondary | Presence of detrusor muscle in resected sample | presence of muscle layer in the pathological specimen (Yes/No) | one day after surgery during pathological evaluation | |
Secondary | Resected specimen's edge | tumor free margin (Yes/No) | one day after surgery during pathological evaluation | |
Secondary | intraoperative complication: bladder perforation | (Yes/No) bladder perforation | intraoperative | |
Secondary | Incidence of obturator reflex | (Yes/No) energy induced obturator reflex | intraoperative | |
Secondary | hematuria | (Yes/No) | postoperative complication up to 2 weeks | |
Secondary | Post-operative catheterization time in hours | time till catheter removal in days | postoperative complication up to 2 weeks | |
Secondary | Postoperative irrigation time in hours | hours for the need of postoperative irrigation | postoperative in hours maximum 1 day | |
Secondary | Recurrence rate of tumors according to time interval | recurrence of tumor in the follow up cystoscopy | 1 year | |
Secondary | Recurrence rate of tumors according to tumor location | recurrence of tumor in the follow up cystoscopy in the same site or in different site | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05429710 -
SOX2 & PDL1 Expression on Urinary Bladder Carcinoma
|
||
Not yet recruiting |
NCT05097105 -
Role of Diffusion -Weighted MRI in Evaluation of Urinary Bladder Masses
|
||
Completed |
NCT02966535 -
The Effect of Prolonged Inspiratory Time on Gas Exchange During Robot-assisted Laparoscopic Surgery With Steep Trendelenburg Position : A Crossover Randomized Clinical Trial
|
N/A | |
Completed |
NCT02977143 -
Positive End-expiratory Pressure-induced Increase in Central Venous Pressure as a Predictor of Fluid Responsiveness in Robot-assisted Laparoscopic Surgery
|
N/A | |
Recruiting |
NCT04144270 -
The Importance of Muscle Function in Patients With Disseminated Bladder Cancer
|
||
Completed |
NCT05946369 -
Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
|
||
Recruiting |
NCT05786716 -
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations
|
Phase 2/Phase 3 | |
Recruiting |
NCT06238479 -
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT02311101 -
Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer
|
Phase 1 | |
Recruiting |
NCT04811846 -
CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood
|
N/A | |
Not yet recruiting |
NCT06465069 -
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
|
Phase 1 | |
Completed |
NCT02857634 -
Confocal Microscopy Dual Band in the Management of Bladder Cancer
|
||
Recruiting |
NCT04561362 -
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT04442724 -
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
|
N/A | |
Recruiting |
NCT04029948 -
Laser vs. Electorsurgical Enbloc Resection of Bladder Tumours
|
N/A | |
Terminated |
NCT03389438 -
Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma
|
Phase 2 | |
Terminated |
NCT02952989 -
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06237920 -
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
|
Phase 2 | |
Completed |
NCT03785925 -
A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer
|
Phase 2 | |
Completed |
NCT03636256 -
Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
|
Phase 1/Phase 2 |